Allergan sues Taro Pharmaceutical over acne treatment
Allergan has filed a complaint against US-based company Taro Pharmaceutical Industries for patent infringement.
The case, which was filed on Thursday, May 1, at the US District Court for the District of Delaware, alleged that Taro had infringed US patent number 9,517,219.
According to the complaint, Taro had sought approval to market a generic version of Allergan’s pharmaceutical product Aczone (dapsone).
Aczone is a prescription medicine used on the skin to treat acne.
Taro had allegedly filed an Abbreviated New Drug Application with the Food and Drug Administration.
Allergan has asked the district court for a permanent injunction, enjoining Taro from bringing the generic drug to market, and an award of damages.
Allergan recently settled a five-year dispute with Apotex over the drug Zymar (gatifloxacin ophthalmic), a treatment for pinkeye.
Today’s stories:
Advocacy groups file brief to support Boehringer
Court grants order to resolve Amgen v FDA dispute
Direct purchasers fight to keep Takeda case alive
UroPep seeks attorneys’ fees from Eli Lilly
Mallinckrodt sues generic company
Did you enjoy reading this story? Sign up to our free newsletters and get stories like this sent straight to your inbox.
